- A prospective study on tumour response assessment methods after 1
- neoadjuvant endocrine therapy in early oestrogen receptor positive breast 2
- cancer 3

- 4 Running title: Tumour response after neoadjuvant endocrine therapy in early
- 5 ER positive breast cancer
- Joanna I. López-Velazco<sup>1\*</sup>, Sara Manzano<sup>1\*</sup>, María Otaño<sup>2</sup>, Kepa Elorriaga<sup>2</sup>, 6
- Núria Bultó<sup>2</sup>, Julio Herrero<sup>2</sup>, Ainhara Lahuerta<sup>1,2</sup>, Virginia Segur<sup>2</sup>, Isabel 7
- Álvarez-López<sup>1,2</sup>, Maria M. Caffarel<sup>1,3#</sup> and Ander Urruticoechea<sup>1,2#</sup> 8
- <sup>1</sup> Biodonostia Health Research Institute, San Sebastian, Spain. <sup>2</sup> Gipuzkoa 10
- Cancer Unit, OSI Donostialdea Onkologikoa Foundation, San Sebastian, 11
- Spain. <sup>3</sup> IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. 12
- \*These authors share first authorship. #These authors share senior and 13
- 14 corresponding authorship.
- # Corresponding authors: Dr Maria M. Caffarel, Biodonostia Health 15
- Research Institute, Paseo Dr Begiristain s/n, San Sebastian, 20014, Spain. 16
- Email: maria.caffarel@biodonostia.org, Tel: +34 943328193. // Dr Ander 17
- Urruticoechea, Onkologikoa Foundation, Paseo Dr Begiristain 121, San 18
- Sebastian, 20014, Spain. Email: anderu@onkologikoa.org, Tel: +34 19
- 943328400. 20
- 21 Conflict of interest: The authors have declared that no conflict of interest
- exists. 22

23

Word count (Introduction to discussion): 3446 24

**Abstract** 

25

Neoadjuvant endocrine therapy (NET) in oestrogen receptor-positive/HER2-26 negative breast cancer (ER+/HER2- BC) allows real-time evaluation of drug 27 28 efficacy and biological changes upon estrogenic deprivation. Clinical and pathological evaluation after NET may be used to obtain prognostic and 29 predictive information of tumour response. Scales developed to evaluate 30 response after neoadjuvant chemotherapy are not useful and there are not 31 32 many validated biomarkers to assess response to NET. In this prospective study, we analysed radiological and pathological tumour response of 104 33 34 postmenopausal ER+/HER2- BC patients, treated with NET for a mean of 7 months. Our results show that radiological evaluation underestimates 35 36 pathological tumour size, although it can be used to assess tumour response. In 37 addition, we propose that the tumour cellularity size (TCS), calculated as the product of the residual tumour cellularity in the surgical specimen and the 38 tumour pathological size, could become a new tool to standardize response 39 assessment to NET. It is simple, reproducible and correlates with the existing 40 biomarkers. Our findings shed light on the dynamics of NET response, 41 challenge the paradigm of the ability of NET to decrease surgical volume and 42 point to the utility of the TCS to quantify the scattered tumour response usually 43 produced by endocrine therapy. 44

- Keywords: Neoadjuvant endocrine therapy, aromatase inhibitors, tumour
- cellularity size, oestrogen receptor (ER) positive breast cancer, pathological and
- 47 radiological tumour response, preoperative endocrine prognostic index (PEPI)
- 48 score, Ki67.

### **Background**

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Oestrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hereafter referred to as ER+ BC) represents almost 70% of all breast malignancies. Antiestrogenic or endocrine therapy is the cornerstone of ER+ BC treatment, being the neoadjuvant (preoperative) setting a very attractive scenario to find novel biomarkers of response and therapeutic strategies<sup>1</sup>. This is an urgent clinical need because long-term resistance to endocrine therapy is a common event<sup>1</sup>. Neoadjuvant endocrine therapy (NET) results in pathological and clinical response rates similar to those observed with neoadjuvant chemotherapy (NCT) although with lower toxicity<sup>2,3</sup>. Three pioneer clinical trials (IMPACT, PROACT and P024) demonstrated that NET is effective in downsizing ER+ BC and facilitating breast-conserving surgery (BCS) and showed greater efficacy for aromatase inhibitors compared with tamoxifen<sup>4–6</sup>. As a consequence of these and other studies, NET, given for 4-8 months, is nowadays recommended by international guidelines for postmenopausal women presenting ER+ BC<sup>7-9</sup>. An important advantage of NET is that it allows "in vivo" evaluation of response, hence granting real-time examination of drug efficacy as well as investigation of the biological and molecular changes that occur after estrogenic deprivation. However, the lack of useful biomarkers of long-term efficacy of therapy has precluded the development of the neoadjuvant strategy for endocrine therapies. In the management of patients under neoadjuvant systemic therapy (either NET or NCT) two important evaluations are performed. First, a preoperative assessment of radiological tumour response (rad-TR) determines the response grade and establishes the surgical strategy<sup>10–12</sup>. Next, surgical specimens are histopathologically evaluated to obtain prognostic information according to pathological tumour response (path-TR) scales 10,12. In the case of BC patients treated with NCT, there are well-stablished parameters to measure tumour response, such as RECIST criteria, Miller & Payne and Sataloff grading scales, and residual cancer burden value 13-16. However, only Preoperative Endocrine Therapy Prognostic Index (PEPI) score and Ki67 levels have been validated as prognostic markers after NET<sup>17–19</sup>. Hence, tumours that show substantial downstaging after NET and present low Ki67 levels and PEPI score at surgery have

an excellent long-term prognosis even without chemotherapy<sup>1,11,19,20</sup>. Both Ki67 levels after NET and PEPI score have been shown to predict long-term outcomes (e.g., relapse-free survival). However, they are not optimal and they are not routinely used due to, among other reasons, a lack of Ki67 measurement standardisation<sup>21</sup>. In the clinical practice, understanding the impact of tumour response to NET in long-term outcome will help clinicians to individualize adjuvant treatment for ER+ BC. In contrast to what happens for NCT, pathologic complete response (pCR) after NET is a rare event and is not a useful marker of prognosis given its low likelihood<sup>3,17,22</sup>. In fact, previous studies suggest that ER+ BC tumours after neoadjuvant systemic therapy present a "diffuse cell loss" response at pathological level, which is characterized by a distribution of the tumour in multiple scattered foci or small groups of tumour cells without affecting overall tumour size<sup>23</sup>.

In this context, there is an urgent need for the identification of robust, reproducible biomarkers of response to NET with long term prognostic value. Ideally, these new biomarkers should be candidates for initial validation in retrospective series. In addition, the mentioned diffuse cell loss in ER+ BC.

reproducible biomarkers of response to NET with long term prognostic value. Ideally, these new biomarkers should be candidates for initial validation in retrospective series. In addition, the mentioned diffuse cell loss in ER+ BC patients treated with NET needs to be better characterized. In order to investigate the dynamics of tumour response, we generated a prospectively collected series of ER+ BC patients treated with NET. We characterised and compared tumour response by ultrasound scan (USS) and/or magnetic resonance imaging (MRI) with pathological tumour size (path-TS). Finally, we described a new biomarker with potential prognostic implications, called tumour cellularity size (TCS), which could help to characterize the response to NET in ER+ BC by an estimation of the diffuse cell loss.

#### **Methods**

107

108

118

128

129

130

131

132

133

134

135

136

137

138

#### Study population

109 We analysed clinical data from a cohort of patients treated in our institution 110 between 2005 and 2019 following a homogenous therapeutic protocol. Data 111 prospectively collected and retrospectively analysed. postmenopausal women with histologically confirmed, untreated, invasive, 112 113 operable, larger than 10 mm and amenable for radiological follow-up, ER+/HER2- non-metastatic breast cancer. Patients had to be treated for at least 114 115 3 months with NET prior to surgery with curative intention. The administered NET was an aromatase inhibitor except contraindicated. Informed consent was 116 obtained from all patients. 117

### Imaging and histopathological analysis

Tumour baseline assessment was performed by breast USS and/or MRI. 119 120 Clinical response by USS was evaluated after 2 months of treatment and repeated every 2 months. MRI and/or USS were also performed before surgery 121 122 to evaluate radiological tumour response (rad-TR). Surgical breast specimens were evaluated by the pathologist to determine pathological tumour response 123 124 (path-TR), tumour size (path-TS) and residual tumour cellularity (%). Clinical (assessed by MRI and USS) or pathological tumour size corresponds to the 125 major diameter of the tumour in millimetres (mm) and T-stage of the primary 126 tumour was defined according to AJCC Cancer Staging Manual<sup>24</sup>. 127

Immunohistochemistry analyses were performed in baseline formalin-fixed paraffin-embedded biopsies and surgical specimens to determine the expression of ER, progesterone receptor (PgR) and Ki67 levels, using international standards<sup>25,26</sup>. ER, PgR and Ki67 were recorded as continuous variables. The positivity cut-off for ER and PgR was  $\geq$ 10% of stained nuclei. Ki67 score was defined as the percentage of tumour cells with Ki67 positive nuclear staining. At least 1000 tumour nuclei were counted per sample, according to the recommendations of Dowsett et al., 2011<sup>25</sup>. The change in Ki67 ( $\Delta$ Ki67) after NET was calculated using the following equation:  $\Delta$ Ki67 = [(Ki67 (%) in surgery specimen) – (Ki67 (%) in baseline biopsy)] / (Ki67 (%) in baseline biopsy). Consequently,  $\Delta$ Ki67 values ranged between -1 to 1.  $\Delta$ Ki67

results were categorized into three groups depending on their magnitude of 139 140 change.  $\Delta Ki67 = -1$  means that Ki67 changes to zero in the surgery specimen.  $\Delta$ Ki67= > -1 to < 0 means that the tumour presented a decrease in Ki67 141 expression. Finally,  $\Delta Ki67 \geq 0$  means that the tumour did not present any 142 change in Ki67 expression or that Ki67 expression in the surgery specimen was 143 greater than the one on baseline biopsy. 144 Rad-TR was defined using mRECIST 1.1 criteria<sup>13</sup>. According with this criteria, 145 146 complete responses (CR) were defined as tumour disappearance and partial responses (PR) were defined as the reduction of the tumour diameter by  $\geq 30\%$ . 147 148 An increase ≥ 20% in tumour diameter was qualified as progressive disease (PD). The rest of situations were qualified as stable disease (SD). 149 Path-TR was quantified using a modified Miller and Payne grading scale<sup>14,27</sup>. In 150 this scale, response grades 1 and 2 (no change or less than 30% loss of tumour 151 cells, respectively) were regarded as SD. Grades 3 and 4 (reduction in tumour 152 cells between 30-90% and > 90%, respectively) were considered as pathologic 153 154 PR. Grade 5 (defined as no malignant cells identifiable in the tumour niche) was 155 considered pathologic CR (pCR). In binary analyses, path-TR was defined as 156 loss of tumour cells  $\geq$  30 % (grades 3-5) and no path-TR as <30% (grades 1-2). 157 Modified PEPI (mPEPI) score was determined on the basis of tumour characteristics of surgical specimen (i.e. tumour size, nodal involvement status 158 and Ki67 staining), as previously published 18,28. Patients were classified into 3 159 mPEPI risk groups (I=0, II=1-3 and III=4+). 160 TCS, the novel score we introduce in this study, was calculated as the product 161 of tumour cellularity in the surgical sample (%) and tumour diameter (path-TS, 162 163 in mm). 164 Statistical analyses Statistical analyses were performed using GraphPad Prism version 9. For the 165 descriptive statistical analyses, minimum, maximum and mean values were 166 167 used. For Gaussians distributions, paired Student's t-test was used to compare differences between two groups. For non-Gaussian distributions, Wilcoxon 168 matched-pairs or Kruskal-Wallis tests were performed. Chi-square or Fisher's 169

tests were used to determine differences between expected frequencies.

Spearman's r coefficient (rho) for analyses, were used to quantify correlations (both with a 95% of confidence interval). P values < 0.05 were considered statistically significant. Unless otherwise specified, histograms represent mean values +/- standard error of the mean (SEM).

171

172

173

#### Results

175

176

198

199

200

201

202

203

204

205

206

#### Tumour characteristics and change in tumour biomarkers after NET

177 104 patients with early ER+/HER2 breast cancer were included in our study. 178 The study population presented a mean age at diagnosis of 69 (47-93) years 179 and the mean NET duration before surgery was 7 months (3-39). The mean tumour size was 25 mm (10-90) assessed by MRI and 18 mm (40-70) by USS. 180 181 The main administered NET drug was letrozole (n=100), but some patients also received anastrozole (n=2), tamoxifen (n=1), or exemestane (n=1). One patient 182 was diagnosed with bilateral disease and her two tumours were independently 183 considered in our analyses. The principal characteristics of the tumours and 184 their surgical management as well as the pathological changes after NET are 185 186 summarised in Table 1. No significant decrease of histological grade was observed after NET (p = 0.12). Ki67, ER and PgR expression was assessed in 187 all tumours pre- and post- NET treatment. As seen in previous studies using 188 similar cohorts (Toi et al. 2011; Martí et al. 2022), NET significantly decreased 189 all these three parameters, being the changes in Ki67 and PgR the most 190 significant (both p < 0.0001, Table 1 and supplementary material, Figure S1). 191 While only 13 patients (12%) were cN+ before treatment, 26 patients (25%) 192 were pN+ at pathological assessment. Regarding pathological tumour response 193 194 to NET, only one case of pCR was recorded and most cases (72%) showed partial path-TR (Table 2). Most patients (81%) fell into low (I, n=34, 35%) and 195 196 intermediate (II, n=45, 46%) mPEPI risk groups. These results are in agreement with the response rates obtained in similar series<sup>8,10,12</sup>. 197

# Radiological examination of tumour size after NET underestimates pathological tumour size

To determine which is the best radiological technique to predict pathological tumour size (path-TS) after NET, we compared tumour size measured by MRI and USS before and after treatment. As expected, radiological tumour size (rad-TS), measured by MRI or USS, both at diagnosis and after NET (just before surgery), significantly correlated with path-TS (Figure 1A-D). Surprisingly, our results showed that path-TS correlated better with tumour size assessed by MRI and USS at diagnosis than after NET (Figure 1A). This may suggest that

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

the radiological evaluation before surgery may not be a very precise technique to assess tumour size after NET. To better visualize this, we compared the mean value of tumour size assessed by each radiological technique, before and after NET, and by path-TS. As shown in Figure 1E, MRI/USS measurements after NET were significantly lower than path-TS and, interestingly, radiological measures at diagnosis were more similar to path-TS than the measures after treatment. Actually, MRI and USS before surgery underestimated path-TS in 77% (76/99) and 92% (84/91) of the cases, respectively. Importantly, we also found that this disagreement in tumour size estimation by imaging and histopathological analysis affects the concordance between radiological (rad-TR) and pathological (path-TR) tumour response (Table 2). Complete rad-TR was observed in 27 (by MRI) and 16 (by USS) patients while only one patient presented a pCR by pathological assessment. To better visualize these discrepancies, we plotted the correlation between rad- and path-TR. As shown in Figure 2A-B, we found that rad-TR assessed by MRI correlated better with path-TR than rad-TR assessed by USS, although both associations were statistically significant. Interestingly, we observed that a considerable number of tumours presented a complete (100%) rad-TR after NET but presented a low path-TR (G2 or G3, highlighted in red in Figure 2A-B). Taken together, our data indicate that the radiological examination of tumour size after NET and before surgery underestimates path-TS bearing surgical implications for the definition of tumour area. Next, we evaluated the association between rad- and path-TR with the two most accepted prognostic markers after NET: Ki67 levels and mPEPI score<sup>11,18,28</sup>. As expected, pathological responders presented significantly lower Ki67 levels at surgery and mPEPI score (Figure 2C-D). Regarding rad-TR, both prognostic markers were associated with tumour response assessed by MRI (Figure 2E-F), but, in the case of USS, there was not association between tumour response and Ki67 and PEPI score (Figure 2G-H). In summary, our data support that radiological evaluation of tumour size after NET underestimates pathological tumour size and indicate that MRI could be more reliable than USS to assess response to NET.

Tumour cellularity size is a new parameter to standardize the assessment

of residual tumour content after NET

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

Diffuse cell loss has been observed as a common pattern of tumour response after neoadjuvant therapies in ER+ (luminal) tumours<sup>23</sup>. In an attempt to better assess tumour response after NET, we propose a novel parameter called tumour cellularity size (TCS). TCS is the product of tumour cellularity (%) and tumour diameter (path-TS, in mm) and estimates the volume of remaining cells in the tumour bed after NET. First, we evaluated how TCS relates to radiological tumour size and response (Figure 3). As seen in Figure 3A, TCS values were much lower than path-TS and more similar to MRI or USS measures after NET compared to rad-TS at diagnosis or path-TS. We then analysed how TCS associates with radiological and pathological response (Figure 3B-D). Our results showed that TCS inversely correlated with path-TR and with MRI rad-TR (Figure 3B-C). However, the association between TCS and rad-TR determined by USS was not significant (Figure 3D), in line with previous results supporting that MRI may be more adequate than USS to quantify response to NET. Taken together, our data indicate that TCS can quantify the tumour "diffuse cell loss" response observed in ER+ BC tumours after NET, and may capture better the biological response of those tumours and explain why the radiological preoperative assessment of tumour size underestimates the path-TS. In order to further evaluate if TCS can be used as a biomarker of response and prognosis for patients undergoing NET, we evaluated its association with changes in Ki67 (\( \Delta Ki67 \)) (Figure 3E-G) and Ki67 levels at surgery (supplementary material, Figure S2), well-established prognostic markers after NET. We observed that ΔKi67 and Ki67 expression at surgery correlated better with TCS than with tumour cellularity or path-TS (Figure 3E-G, and supplementary material, Figure S2A-C). Consequently, tumours with high residual Ki67 expression ( $\Delta$ Ki67 > 0 and high Ki67 expression at surgery) also present a high TCS, suggesting that TCS could be a promising biomarker of response to NET. Finally, to identify an initial cut-off value for which TCS can divide patients

responding to NET from no responder patients, we analysed the relationship of

As mentioned before, TCS is positively correlated with Ki67 at surgery and  $\Delta$ Ki67 (Figure S3). Tumours with TCS <2.5 mm (Q1) showed significantly lower Ki67 levels at surgery and  $\Delta$ Ki67 compared with tumours with TCS  $\geq$  2.5 mm (Q2, Q3 and Q4, Figure 4), suggesting that a TCS value <2.5 mm could be used as a good cut-off value to identify patients responding to NET. However, more studies in independent cohorts with associated survival data are needed.

#### **Discussion**

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

There are different reasons why neadjuvant endocrine therapy (NET) is a very promising and attractive therapeutic strategy for ER+ BC patients. First, it is less toxic than neoadjuvant chemotherapy albeit resulting in similar pathological and clinical response rates and, indeed, it is already recommended by international guidelines for post-menopausal women<sup>3</sup>. Finally, it represents an ideal scenario for clinical research as it allows real time investigation of drug efficacy and of the molecular and biological changes in tumours after endocrine treatment. This may lead to the identification of novel biomarkers of response and new therapeutic strategies. However, NET remains an underused tool for ER+ BC because monitoring response is challenging, among other reasons<sup>3,29</sup>. Many NET clinical trials use the radiological response rate (by pre-operative evaluation with USS, mammography or MRI using RECIST 1.1 criteria) and improvement of BCS rates as a primary objective to demonstrate effectiveness<sup>3,11,12</sup>. However, our results, obtained from a prospectively collected series of 104 ER+ BC patients treated with NET, prove that the preoperative radiological evaluation after NET underestimates path-TS. Previous reports have also shown that radiological and clinical evaluation after NET underestimate the lesion size<sup>10</sup>, although Reis and cols found this difference negligible<sup>30</sup>. Clinically, these discrepancies between radiological pathological responses may have strong surgical implications for the definition of lesion area and our data suggest that the radiological evaluation of tumour size should not be determinant to plan the resection area. In fact, the AJCC recommends that imaging findings after NET, NCT and radiotherapy are not considered elements of initial clinical staging<sup>24</sup>. In addition, our data show that radiological complete responses almost never parallel pCR. In our series, 26% and 15% of patients showed complete radiological response by MRI and USS, respectively, but only 1 patient achieved pCR. In fact, pCR after NET is a rare event and only occurs in less than 1% of the cases<sup>3</sup>. Usually, residual disease is found even in very good responder tumours, in the form of microscopically scattered residual cancer nests in the tumour bed [30]. This scattered or diffuse cell loss response is also observed after neoadjuvant chemotherapy in ER+ tumours<sup>23</sup>.

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

While pathological assessment considers the maximum area occupied by the tumour and does not capture this scattered response, radiological evaluation after NET may reflect the diffuse cell loss response. This could explain why rad-TS after NET did not reflect path-TS in the surgery specimens in our cohort and challenges the paradigm of NET as a tool to increase the BCS rates for ER+ BC. The difference between radiological and pathological evaluation of neoadjuvant systemic treatment (NST) is less frequently observed in triplenegative and non-luminal HER2+ tumours, which tend to present a shrinkage or concentric response (also called tumour collapse) to NST<sup>23</sup>. Nevertheless, we should also take into consideration that the complete response assessed by MRI may capture biological events with potential prognostic/predictive value, including normalization of tumour vessels. Hence, the event of CR by MRI, even without pCR, may define a prognostic category that deserves further study. Despite the discrepancies between radiological and pathological evaluation of tumour response to NET, clinical and radiological monitoring of tumour response during the course of NET are necessary to early detect disease progression. Our data indicate that MRI is preferable than USS to assess response to NET, as 1) path-TR correlated better with rad-TR assessed by MRI than by USS and 2) MRI rad-TR was significantly associated with reduction of Ki67 in the surgical specimen and lower mPEPI score, the two most accepted prognostic markers after NET<sup>11,18,28</sup>. This association was not statistically significant in the case of USS. Our results are in agreement with previous reports supporting the use of MRI as the most accurate tool among other methods (clinical examination, USS and mammography) to assess tumour response to NST in breast cancer<sup>3,31</sup>. As mentioned above, the diffuse cell loss response observed in ER+ tumours as a response to NST represents a challenge to evaluate tumour response to NET. We hypothesize that the parameter tumour cellularity size (TCS), presented herein, can be used to assess the scattered response to NET as it estimates the multiple scattered foci of tumour cells in the tumour niche. TCS is the product of tumour cellularity (%) and tumour diameter (path-TS, in mm) in the post-treatment surgical sample. We found that TCS significantly associated

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

with rad-TR evaluated with MRI. As previously discussed, only PEPI score and Ki67 expression under treatment are validated prognostic markers for NET<sup>17–19</sup>. Importantly, TCS correlated better with ΔKi67 than the percentage of tumour cellularity in the post-treatment sample and the path-TS. This may indicate that reduction in Ki67 expression is related to the tumour cellularity content even when the path-TS does not change after NET. The association between TCS and mPEPI score could not be evaluated as they are not independent variables since both include path-TS in their calculation<sup>28</sup>.

In summary, our results shed light on two clinically relevant and unanswered questions in the context of NET highlighted by Sella and cols<sup>3</sup>. One of them is which is the optimal imaging technique to pre-surgically evaluate residual disease after NET. Our data supports the use of MRI over USS, but also prove

Additional information

- Supplementary information is available at BJC's website
- 368 **Acknowledgements**

366

367

- 369 We are grateful to the members of our laboratory for critical discussion of this
- work and to the Pathology Services of Hospital Donostia and Onkologikoa 370
- 371 Foundation for technical assistance.
- **Ethics Approval** 372
- The study was conducted in accordance with the Declaration of Helsinki and 373
- 374 Good Clinical Practice guidelines as well as authorised by the Spain Health
- Authority and the local Ethics Committee. 375
  - **Authors' contributions**
- JILV, SM, AU and MMC analysed the data and wrote the manuscript. AU 377
- designed the study. AU and MMC co-supervised the study. KE analysed 378
- histopathology. VS and NB analysed imaging data. JILV, MO, AL, JH, IAL and 379
- AU collected and analysed patient data. 380
- **Funding** 381
- This work was funded by Instituto de Salud Carlos III (ISCIII) grants: 382
- PI21/01208, PI20/01253, CP18/00076 and FI19/00193 co-funded by the 383
- European Union, Basque Department of Health (2020111040), Fundación 384
- 385 SEOM (SEOM Avon Fellowship 2020) and Ikerbasque Basque Research
- Foundation. The group also received funds from the breast cancer patient's 386
- charity Katxalin and from Roche Farma S.A. JILV is funded by an AECC PhD 387
- Fellowship (PRDGI19007LOPE). 388
- Data availability statement 389
- The data for this study are available upon reasonable request. 390
- Consent for publication and competing interests 391
- 392 We verify that each author consents the publication of this manuscript and
- 393 authors have no conflicts of interest to declare.

## REFERENCES

- 1. Burstein, H. J. Systemic Therapy for Estrogen Receptor-Positive, HER2-
- 396 Negative Breast Cancer. *N. Engl. J. Med.* **383**, 2557–2570 (2020).
- 397 2. Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W.,
- Isakoff, S. J. et al. Neoadjuvant endocrine therapy for estrogen receptor-
- positive breast cancer a systematic review and meta-Analysis. JAMA
- 400 Oncol. 2, 1477–1486 (2016).
- 3. Sella, T., Weiss, A., Mittendorf, E. A., King, T. A., Pilewskie, M., Giuliano,
- A. E. et al. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.
- 403 *JAMA Oncol.* **7**, 1700–1708 (2021).
- 404 4. Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin,
- J., Vinholes, J. et al. Preoperative treatment of postmenopausal breast
- 406 cancer patients with letrozole: A randomized double-blind multicenter
- 407 study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 12, 1527–1532 (2001).
- 408 5. Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y.,
- Petrakova, K. et al. Comparison of anastrozole versus tamoxifen as
- preoperative therapy in postmenopausal women with hormone receptor-
- positive breast cancer: the Pre-Operative "Arimidex" Compared to
- 412 Tamoxifen (PROACT) trial. *Cancer* **106**, 2095–2103 (2006).
- 413 6. Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer,
- J.-U. et al. Neoadjuvant treatment of postmenopausal breast cancer with
- anastrozole, tamoxifen, or both in combination: the Immediate
- Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen
- 417 (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. Off. J.
- 418 Am. Soc. Clin. Oncol. 23, 5108–5116 (2005).
- 7. Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N.,
- Hwang, E. S. et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and
- Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol. 39,
- 422 1485–1505 (2021).
- 423 8. Martí, C., Yébenes, L., Oliver, J. M., Moreno, E., Frías, L., Berjón, A. et al.
- The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like

- Breast Cancers and Its Prognostic Significance: Results from a Single-425
- Institution Prospective Cohort Study. Curr. Oncol. 29, 2199–2210 (2022). 426
- 427 9. Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P.,
- 428 Rubio, I. T. et al. Early breast cancer: ESMO Clinical Practice Guidelines
- for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. 429
- Med. Oncol. 30, 1674 (2019). 430
- 431 10. Lerebours, F., Rivera, S., Mouret-Reynier, M. A., Alran, S., Venat-Bouvet,
- L., Kerbrat, P. et al. Randomized phase 2 neoadjuvant trial evaluating 432
- anastrozole and fulvestrant efficacy for postmenopausal, estrogen 433
- receptor-positive, human epidermal growth factor receptor 2-negative 434
- breast cancer patients: Results of the UNICANCER CARMINA 02 french 435
- 436 trial. Cancer 122, 3032–3040 (2016).
- 11. Ueno, T., Saji, S., Masuda, N., Kuroi, K., Sato, N., Takei, H. et al. Impact 437
- of clinical response to neoadjuvant endocrine therapy on patient 438
- 439 outcomes: A follow-up study of JFMC34-0601 multicentre prospective
- neoadjuvant endocrine trial. ESMO Open 3, (2018). 440
- 12. Skriver, S. K., Laenkholm, A. V., Rasmussen, B. B., Handler, J., 441
- Grundtmann, B., Tvedskov, T. F. et al. Neoadjuvant letrozole for 442
- 443 postmenopausal estrogen receptor-positive, HER2-negative breast
- cancer patients, a study from the Danish Breast Cancer Cooperative 444
- Group (DBCG). Acta Oncol. (Madr). 57, 31–37 (2018). 445
- Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, 446 13.
- D., Ford, R. et al. New response evaluation criteria in solid tumours: 447
- 448 Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247
- (2009).449
- Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., 450 14.
- Smith, I. et al. A new histological grading system to assess response of 451
- breast cancers to primary chemotherapy: Prognostic significance and 452
- 453 survival. Breast 12, 320-327 (2003).
- 15. Sataloff, D. M., Mason, B. A., Prestipino, A. J., Seinige, U. L., Lieber, C. 454
- P. & Baloch, Z. Pathologic response to induction chemotherapy in locally 455
- advanced carcinoma of the breast: a determinant of outcome. J. Am. 456

- Coll. Surg. 180, 297-306 (1995). 457
- Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M. et al. 16. 458
- 459 Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated
- 460 With Residual Cancer Burden and Breast Cancer Subtype. J. Clin.
- Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 1049-1060 (2017). 461
- Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, 17. 462
- 463 H. et al. Predictive factors of 5-year relapse-free survival in HR+/HER2-
- breast cancer patients treated with neoadjuvant endocrine therapy: 464
- pooled analysis of two phase 2 trials. Br. J. Cancer 122, 759–765 (2020). 465
- 18. Suman, V. J., Ellis, M. J. & Ma, C. X. The ALTERNATE trial: Assessing a 466
- biomarker driven strategy for the treatment of post-menopausal women 467
- with Er+/Her2- invasive breast cancer. Chinese Clinical Oncology vol. 4 468
- (2015).469
- Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De 470 19.
- Salvo, G. L. et al. De-escalated therapy for HR+/HER2+ breast cancer 471
- 472 patients with Ki67 response after 2-week letrozole: Results of the
- PerELISA neoadjuvant study. Ann. Oncol. 30, 921–926 (2019). 473
- Smith, I., Robertson, J., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C. 474 20.
- et al. Long-term outcome and prognostic value of Ki67 after perioperative 475
- endocrine therapy in postmenopausal women with hormone-sensitive 476
- early breast cancer (POETIC); an open-label, multicentre, parallel-group. 477
- randomised, phase 3 trial. Lancet Oncol. 21, 1443–1454 (2020). 478
- Ellis, M. J., Suman, V. J., Hoog, J., Goncalves, R., Sanati, S., Creighton, 479 21.
- C. J. et al. Ki67 proliferation index as a tool for chemotherapy decisions 480
- during and after neoadjuvant aromatase inhibitor treatment of breast 481
- cancer: Results from the American college of surgeons oncology group 482
- Z1031 trial (alliance). J. Clin. Oncol. 35, 1061–1069 (2017). 483
- 22. Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, 484
- N. et al. Pathological complete response and long-term clinical benefit in 485
- 486 breast cancer: The CTNeoBC pooled analysis. Lancet 384, 164–172
- (2014).487

- 23. Heil, J., Kuerer, H. M., Pfob, A., Rauch, G., Sinn, H. P., Golatta, M. et al. 488
- Eliminating the breast cancer surgery paradigm after neoadjuvant 489
- 490 systemic therapy: current evidence and future challenges. Annals of
- Oncology vol. 31 61-71 (2020). 491
- Hortobagyi, G. N., Connolly, J. L., Orsi, C. J. D., Edge, S. B., Mittendorf, 492 24.
- E. A., Rugo, H. S. et al. AJCC Cancer Staging Manual 8th Edition. 493
- 494 Definitions (2020). doi:10.32388/b30ldk.
- 495 25. Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C.,
- Cuzick, J. et al. Assessment of Ki67 in Breast Cancer: Recommendations 496
- from the international Ki67 in breast cancer working Group. Journal of the 497
- National Cancer Institute vol. 103 1656–1664 (2011). 498
- 26. Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. 499
- L., Badve, S. et al. American Society of Clinical Oncology/College Of 500
- American Pathologists guideline recommendations for 501
- 502 immunohistochemical testing of estrogen and progesterone receptors in
- breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28, 2784-503
- 504 2795 (2010).
- Skriver, S. K., Jensen, M. B., Knoop, A. S., Eilertsen, B. & Laenkholm, A. 505 27.
- V. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole 506
- in patients with early oestrogen receptor-positive breast cancer: Analysis 507
- from a nationwide phase II DBCG trial. Breast Cancer Res. 22, (2020). 508
- Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S. et 509 28.
- al. Outcome prediction for estrogen receptor-positive breast cancer based 510
- on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. 511
- Cancer Inst. 100, 1380–1388 (2008). 512
- Martí, C. & Sánchez-méndez, J. I. The present and future of neoadjuvant 513 29.
- endocrine therapy for breast cancer treatment. Cancers vol. 13 (2021). 514
- 30. Reis, J., Lindstrøm, J. C., Boavida, J., Gjesdal, K. I., Park, D., Bahrami, N. 515
- et al. Accuracy of breast MRI in patients receiving neoadjuvant endocrine 516
- therapy: comprehensive imaging analysis and correlation with clinical and 517
- pathological assessments. Breast Cancer Res. Treat. 184, 407–420 518
- (2020).519

Fowler, A. M., Mankoff, D. A. & Joe, B. N. Imaging Neoadjuvant Therapy 31. 520 Response in Breast Cancer. Radiology 285, 358-375 (2017). 521

Figure legends

- Figure 1. Comparison between pathological and radiological tumour size 524
- 525 before and after neoadyuvant endocrine treatment (NET). (A-D) Correlation
- 526 of pathological tumour size (path-TS) with MRI (A and C) and USS (B and D)
- measurements at diagnosis (A-B) and after NET (C-D). Spearman correlation 527
- 528 coefficients (rho) and p values are shown. (E) Comparison of radiological
- tumour size (assessed by MRI and USS at diagnosis and after NET) with path-529
- TS. p values were calculated using Kruskal-Wallis test. 530
- Figure 2. Evaluation of radiological tumour response (rad-TR) after NET by 531
- comparison with pathological tumour response (path-TR) and prognostic 532
- biomarkers for NET. (A-B) Rad-TR was assessed by MRI (A) and USS (B) and 533
- evaluated by mRECIST 1.1 criteria. Path-TR was evaluated using a modified 534
- Miller and Payne grading scale. In the upper square, tumours presenting 535
- complete response by MRI (A) or USS (B), but partial response (G2-G3) by 536
- path-TR, are highlighted in red. (C, E and G) Analysis of Ki67 levels at surgery 537
- in tumours classified according to theip values were calculated (All). (D. F and 538
- H) Contingency analyses of the association between modified PEPI (mPEPI) 539
- score and path-TR (D) and rad-TR by MRI (F) or USS (H). p values were 540
- calculated using Kruskal-Wallis test (A-C, E, G) or Chi-square test (D, F and H). 541
- CR: complete response, PR: partial response, SD: stable disease, and PD: 542
- progression disease. 543
- Figure 3. Tumour cellularity size (TCS) as a new parameter to measure 544
- 545 response to NET. (A) Comparison of radiological tumour size (assessed by
- MRI and USS, before and after NET) with TCS. Dotted line indicates the mean 546
- 547 of path-TS obtained for those tumours. (B-D) Association between TCS and
- pathological (path-TR) (B) and radiological response assessed by MRI (C) or 548
- USS (D). (E-G) Association between TCS (E), tumour cellularity (F) and 549
- pathological tumour size (path-TS) (G) with changes in Ki67 (△Ki67) after NET. 550
- p values were calculated using Kruskal-Wallis test. 551
- Figure 4. Identification of a tumour cellularity size (TCS) cut-off value to 552
- discriminate patients according to their response to NET. (A-B) Ki67 levels 553

at surgery (A) and  $\Delta$ Ki67 (B) in tumours with low (quartile 1, Q1) versus high 554 (Q2, Q3 and Q4) TCS. p values were calculated using Mann Whitney test. 555






Figure 2



ΔKi67

n = 91

5



20

ΔKi67

n = 94

-1

5

≥ 0

12

>-1a 0

74

20

ΔKi67

n = 101

-1

5

≥ 0

13

> -1 a 0

76

≥ 0

15

>-1a 0

Figure 4




Table 1. Histopathological information and surgical management of tumours included in our series. \*One patient was diagnosed with bilateral disease and her two tumours were independently considered in the histopathological analysis and in its surgical management. <sup>a</sup>One tumour was not evaluable for biological characteristics at surgery because the patient achieved a pCR. c/yp axillary node status was determined clinically and pathologically before and after NET, respectively. BCS: Breast-conserving surgery. N/A: not available.

Characteristics	Before NET (n = 105*)	After NET $(n = 104^a)$
Histological grade [n (%)]	,	,
1	23 (22)	34 (33)
II	78 (74)	69 (66)
III	4 (4)	1 (1)
Histological type [n (%)]		
Ductal	86 (82)	85 (82)
Lobular	10 (10)	12 (12)
Other special type	9 (8)	7 (6)
c/yp axillary node status [n (%)]		
Negative	91 (87)	72 (69)
Positive	13 (12)	26 (25)
N/A	1 (1)	7 (6)
Positive cells (%) [mean (range)]		
Ki67	20 (3-60)	9 (0-75)
Oestrogen receptor	94 (20-100)	90 (0-99)
Progesterone receptor	63 (1-100)	15 (0-99)
Breast surgery performed [n (%)]*		
BCS		95 (90)
Modified radical mastectomy		10 (10)

Table 2. Radiological (Rad-) and pathological (Path-) tumour response (TR) after NET. Rad-TR was evaluated by mRECIST 1.1 criteria and path-TR was measured using a modified Miller and Payne grading scale. N/A: not available.

Rad-TR type [n (%)]	MRI	USS	Path-TR [n (%)]
N/A	7 (7)	14 (13)	0 (0)
Complete	27 (26)	16 (15)	1 (1)
Partial	40 (38)	49 (47)	76 (72)
Stable disease	29 (27)	24 (23)	28 (27)
Progressive disease	2 (2)	2 (2)	0 (0)